Clinical Trials on Chronic Hepatitis C Genotype 1b

Total 3398 results

Sandoz

Completed

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

Chronic Hepatitis C
Sandoz

Completed

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

Chronic Hepatitis C
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of MP-424

Chronic Hepatitis C

Korea, Republic of
Debiopharm International SA

Completed

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Chronic Hepatitis C

United States, Germany, Australia, United Kingdom, France, Netherlands, Canada, New Zealand, Italy, Poland, Austria, Estonia, Spain, Sweden, Puerto Rico, Czech Republic
Foundation for Liver Research

Completed

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (ImmunoDual)

Chronic Hepatitis C

Netherlands
Bristol-Myers Squibb

Completed

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Chronic Hepatitis C

United States, Canada
St Vincent's Hospital Melbourne
Merck Sharp & Dohme LLC

Unknown

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6)

Chronic Hepatitis C

Australia
Pfizer

Completed

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Assiut University

Unknown

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Chronic Hepatitis c
Debiopharm International SA

Completed

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Hepatitis C | Liver Disease

Germany, Sweden, United Kingdom, Poland
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
Ain Shams University

Completed

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Metabolic Syndrome | Chronic Hepatitis c

Egypt
Hepatitis Resource Network
Integrated Therapeutics Group; Subsidiary of Schering-Plough

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

HIV Infections | Chronic Hepatitis C Infection in HIV-Infected Persons

United States
Hepatitis Resource Network
Hoffmann-La Roche

Unknown

HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy

HIV Infections | Chronic Hepatitis C Infection in HIV Infected Persons

United States
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
University of Roma La Sapienza

Unknown

Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)

Non Alcoholic Fatty Liver Disease | Chronic Hepatitis C Virus

Italy
Egyptian Liver Hospital

Unknown

Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

Hepatitis C Virus Infection, Response to Therapy of

Egypt
HaEmek Medical Center, Israel
AbbVie

Completed

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B

HCV Coinfection

Israel
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Duke University
Novartis Pharmaceuticals

Completed

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

Chronic Hepatitis C | Organ Transplantation | Immunosuppression

United States
Hospital Carlos III, Madrid

Unknown

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (PERICO)

Chronic Hepatitis C

Spain
The University of Hong Kong

Active, not recruiting

Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong

Chronic Hepatitis C | Intravenous Drug Usage

Hong Kong
University of North Carolina, Chapel Hill
National Institutes of Health (NIH); National Center for Complementary and...

Completed

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

Chronic Hepatitis C | Oxidative Stress

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Miguel Santín

Completed

Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients (CONTRA)

Chronic Hepatitis C

Spain
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan

Chronic Hepatitis C

Taiwan, Israel
Johann Wolfgang Goethe University Hospital

Completed

Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV

Chronic Hepatitis C

Netherlands, Germany, France
National Taiwan University Hospital

Completed

Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study

Chronic Hepatitis C | Hepatic Fibrosis

Taiwan
Debiopharm International SA

Completed

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Hepatitis C | Liver Disease

United States, France
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

India
Southern Illinois University

Completed

Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

Hepatitis C Infection

United States
Universidade Federal do Rio de Janeiro
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Oswaldo Cruz... and other collaborators

Unknown

Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis (CELTHEP-02)

Liver Cirrhosis Due to Virus C Chronic Hepatitis

Brazil
Asociacion para el Estudio del Higado
Merck Sharp & Dohme LLC

Unknown

Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study ((CHINCHERO))

HCV Infection
University of Nebraska

Withdrawn

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
Melbourne Health
Hoffmann-La Roche; Monash University; The University of New South Wales; St Vincent... and other collaborators

Completed

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Chronic Hepatitis C

Australia
University of California, San Francisco

Completed

Natural History of Hepatitis C in Patients With Normal Liver Tests

Chronic Hepatitis C
AbbVie

Completed

An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs (Maviret PMS)

Hepatitis C

Korea, Republic of
Stanford University
Gilead Sciences

Completed

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

PT-NANBH

United States
Stanford University
Yale University; Janssen Scientific Affairs, LLC

Withdrawn

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

PT-NANBH

United States
AbbVie
IST GmbH, Germany

Completed

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C
Hospital Carlos III, Madrid

Completed

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies (PILOT-NR)

HIV Infections | Chronic Hepatitis C

Spain
Valme University Hospital

Completed

Treatment Insulin Resistence in HCV G-1 Patient (TRIC-1)

Chronic Hepatitis C

Spain

3

Subscribe